College questions dabigatran pressure
The RACGP has slammed the roll-out of dabigatran in Australia, accusing the drug’s manufacturer of pressuring government into subsidising the drug.
In a scathing submission to the Federal Government's review of anticoagulants for AF, the college questioned the safety of Boehringer Ingelheim's product-familiarisation program for dabigatran (Pradaxa).
It warned that new anticoagulants were being introduced before appropriate guidelines, prescribing practices and monitoring infrastructure were in place.
"We have seen rigorous activity by the drug company to